Open AccessClinicopathological response to neoadjuvant therapies and pathological complete response as a biomarker of survival in human epidermal growth factor receptor-2 enriched breast cancer – A retrospective cohort study
Author(s) -
Matthew G. Davey,
Eoin Kerin,
Clara O'Flaherty,
Elizabeth A. Maher,
Vinitha Richard,
Peter McAnena,
Ray McLaughlin,
Karl Sweeney,
Michael Kevin Barry,
Carmel Malone,
W. Wyns,
Osama Soliman,
Nicola Miller,
Maccon Keane,
Aoïfe Lowery,
Michael J. Kerin
Publication year - 2021
Publication title -
the breast
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 78
eISSN - 1532-3080
pISSN - 0960-9776
DOI - 10.1016/j.breast.2021.06.005
Subject(s) - medicine , breast cancer , hazard ratio , oncology , proportional hazards model , biomarker , neoadjuvant therapy , cancer , gynecology , confidence interval , biochemistry , chemistry
Human epidermal growth factor receptor-2 (HER2) is overexpressed in 20-25% of breast cancers. Complete eradication of disease following neoadjuvant therapies and chemotherapy has been referred to as pathological complete response (pCR).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom